Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DEBIO 1143 + carboplatin + paclitaxel
- Development stage
- Discontinued
- Lead developer
- Debiopharm International
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
DEBIO 1143 + carboplatin + paclitaxel is a combination therapy investigated for the treatment of locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN). DEBIO 1143 (also called xevinapant) is an orally available small molecule antagonist of inhibitor of apoptosis proteins (IAPs), designed to promote apoptosis (programmed cell death) and enhance antitumor immunity; it acts as a radiosensitizer and may potentiate the effect of chemoradiotherapy. Carboplatin and paclitaxel are standard chemotherapeutic agents commonly used in the treatment of various solid tumors; carboplatin is a platinum coordination complex causing DNA crosslinking and apoptosis, while paclitaxel stabilizes microtubules, inhibiting mitosis[1][5].
- Brand names
- xevinapant
- Other names
- DEBIO 1143 + carboplatin + paclitaxel
02
Targets
Inhibitor of apoptosis protein–caspase and inhibitor of apoptosis protein–receptor-interacting protein kinase protein–protein interfacesXIAPBIRC2 (Cellular inhibitor of apoptosis protein 1)DNAIAP (Inhibitor of apoptosis protein family)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on DEBIO 1143 + carboplatin + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DEBIO 1143 + carboplatin + paclitaxel.